The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

With a landmark U.S. approval  Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit ...

Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

BRIDGEWATER – Shares of Insmed, a pharmaceutical firm at the intersection of Route 202-206 and Allen Road, jumped 8% on the NASDAQ after the federal Food and Drug Administration approved the company's ...

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease non-cystic fibrosis bronchiectasis (NFCB).

Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to a potential multibillion ...

The FDA has approved Insmed’s brensocatib, the first treatment for non-cystic fibrosis bronchiectasis, a chronic and progressive lung disease affecting about 500,000 people in the U.S. The drug was ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...